{
    "eid": "2-s2.0-84952980874",
    "title": "Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): A phase 2b randomised, controlled, partly blinded trial",
    "cover-date": "2016-01-01",
    "subject-areas": [
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Immunology",
            "@code": "2403"
        },
        {
            "$": "Epidemiology",
            "@code": "2713"
        },
        {
            "$": "Virology",
            "@code": "2406"
        }
    ],
    "keywords": [],
    "authors": [
        "Samir K. Gupta"
    ],
    "citedby-count": 11,
    "ref-count": 31,
    "ref-list": [
        "European AIDS Clinical Society Guidelines Version 7.1. European AIDS Clinical Society",
        "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents",
        "Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine",
        "Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment",
        "Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy",
        "High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin",
        "Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies lessons learned",
        "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir",
        "Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort",
        "Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea",
        "AIDS Clin Care",
        "Reye's syndrome in adult with AIDS",
        "Lactic acidosis complicating the acquired immunodeficiency syndrome",
        "Highly selective action of triphosphate metabolite of 4\u2032-ethynyl D4T: A novel anti-HIV compound against HIV-1 RT",
        "Novel 4\u2032-Substituted Stavudine Analog with Improved Anti-Human Immunodeficiency Virus Activity and Decreased Cytotoxicity",
        "In Vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations",
        "Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects",
        "Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy",
        "Retention of metabolites of 2\u2032,3\u2032-didehydro-3\u2032-deoxy- 4\u2032-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells",
        "Tenofovir disoproxil fumarate",
        "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: A randomized trial",
        "Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection",
        "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202",
        "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study",
        "Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study",
        "Regional adiposity and morbidity",
        "Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG study A5224s",
        "Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "affilname": "Bristol-Myers Squibb",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Cape Town",
            "affilname": "Desmond Tutu Health Foundation",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "Lima",
            "affilname": "Hospital Nacional Cayetano Heredia",
            "affiliation-country": "Peru"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Indianapolis",
            "affilname": "Indiana University School of Medicine",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Cleveland",
            "affilname": "Case Western Reserve University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Mexico City",
            "affilname": "Centro Glucomedi",
            "affiliation-country": "Mexico"
        },
        {
            "affiliation-city": "Bloemfontein",
            "affilname": "Josha Research",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "West Palm Beach",
            "affilname": "Triple O Research Institute PA",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "US Code of Federal Regulations",
        "European Commission",
        "European Commission"
    ]
}